ClinicalTrials.gg
CompletedNCT01971164Updated Jul 14, 2014

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

A Phase 1 interventional study of JTZ-951 and Placebo in Anemia of Chronic Kidney Disease, sponsored by Akros Pharma Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-07-14.

Sponsored by Akros Pharma Inc. (part of Shionogi) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.

Enrollment
274th of 395
29 · median 72
Started
2013
with 25 others
Phase 1
52 of 464
2 open now
Registered
245th of 464
by date

Among the 464 studies in Anemia with a site in United States, this one is the 274th largest by enrollment of the 395 interventional ones that give a count, is one of 26 that started in 2013, is one of 52 in phase 1, and was the 245th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 464 studies in Anemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of sequential ascending doses of JTZ-951 administered for 15 days in anemic subjects with end-stage renal disease (ESRD) receiving hemodialysis.

03

Conditions studied

  • Anemia of Chronic Kidney Disease

Keywords

  • anemia
  • chronic kidney disease
  • hemodialysis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have ESRD and have been receiving maintenance hemodialysis for at least 12 weeks prior to the Screening Visit
  • Body weight (post-dialysis weight) greater than 45.0 kg and a between 20.0 and 40.0 kg/m2 (inclusive) at the Screening Visit
  • value as defined in the protocol
  • Meet the erythropoiesis-stimulating agent (ESA) therapy criteria at the Screening Visit as defined in the protocol

Exclusion criteria

Exclusion Criteria:

  • Transferrin saturation and ferritin levels at the Screening Visit as defined in the protocol
  • Anemia due to known causes other than chronic kidney disease
  • Known history of hyporesponsiveness to ESAs
  • Acute coronary syndrome (e.g., myocardial infarction) within 1 year prior to Screening visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Dose 1 JTZ-951 or Placebo

    Tablets, 1 dose per day for 15 days

    Drug: JTZ-951 · Drug: Placebo

  • Experimental
    Dose 2 JTZ-951 or Placebo

    Tablets, 1 dose per day for 15 days

    Drug: JTZ-951 · Drug: Placebo

  • Experimental
    Dose 3 JTZ-951 or Placebo

    Tablets, 1 dose per day for 15 days

    Drug: JTZ-951 · Drug: Placebo

  • Experimental
    Dose 4 JTZ-951 or Placebo

    Tablets, 1 dose per day for 15 days

    Drug: JTZ-951 · Drug: Placebo

Interventions

  • Subjects will receive JTZ-951 or Placebo

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events

    Time frame: 15 days

  2. Vital signs and 12 lead ECGs

    Time frame: 15 days

  3. Cmax (maximum concentration)

    Time frame: 15 days

  4. tmax (time to reach maximum concentration)

    Time frame: 15 days

  5. t1/2 (elimination half-life)

    Time frame: 15 days

  6. AUC (area under the concentration-time curve)

    Time frame: 15 days

  7. AR (accumulation ratio)

    Time frame: 15 days

  8. RBC (red blood cell) count

    Time frame: 15 days

  9. Hgb (hemoglobin)

    Time frame: 15 days

  10. TSAT (transferrin saturation)

    Time frame: 15 days

  11. serum ferritin

    Time frame: 15 days

07

Study locations

5 sites
  • Lakewood, Colorado, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Minneapolis, Minnesota, United States
  • Saint Paul, Minnesota, United States
08

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of May 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2013
First posted
Oct 29, 2013
Start
May 2013
Primary completionActual
May 2014
CompletionActual
Jul 2014
Last update
Jul 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01971164
Lead sponsor
Akros Pharma Inc.
Responsible party
Sponsor
First posted
Oct 29, 2013
Start date
May 2013
Primary completion
May 2014
Completion
Jul 2014
Last update
Jul 14, 2014

Study contacts

Hideyuki Yamamoto
study chair · Akros Pharma Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enarodustat

Start the discussion